Argenx Shares Plunge After Autoimmune-Disease Trial Halt

The stock was down 18%, wiping out year-to-date gains after the biotech stopped a late-stage clinical trial of its Vyvgart drug due to lack of efficacy.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。